title: [Antiblastic hypoxic stop-flow perfusion in the treatment of liver metastasis: preliminary results].
abstract: METHODS
  27 patients (14 men and 13 women aged 35 to 71 years; average: 59 years), with 3-11 months' follow-up (average: 5 months) were treated for hepatic metastases (17/22 from colorectal, 10/22 from other primary tumors) with hypoxic locoregional hepatic perfusion. Sixteen of 22 patients had been pretreated with resection, systemic chemotherapy or freeflow locoregional infusion. Our protocol consists in blocking arterial flow with an occlusion balloon catheter inflated in the hepatic artery; the main catheter channel is connected with a pump system and 250-300 ml saline with 30-40 mg Mitomycin C are perfused in the arterial hepatic system. Embolization with a gelatin sponge is performed after the end of perfusion.
  
  
  RESULTS
  19/27 patients are still alive, and 8/27 are dead but death was caused by the progression of intrahepatic disease in only 2/27 (7%). Iatrogenic lesions of the arterial wall were shown at follow-up DSA in 15/22 patients (56%). Thirteen CR (48%) and 9 PR (33%) were demonstrated at CT follow-up, amounting to 81% of objective responses. Follow-up showed a clinical CR in 12/18 symptomatic patients (66%). No case of hematologic toxicity was observed. Mean CEA values changed from 129 to 10.60. Twelve of 27 patients exhibited mild posttreatment sequels, none of them lasting longer than three days; ischemic cholecystitis was seen in 3/15 cases (14%).
  
  
  CONCLUSIONS
  The occlusion catheters on the market are not optimal for this procedure; the axillary percutaneous approach is advantageous. CR rate was very high in our series but the objective response rate doses do not differ from those in the series with free-flow procedures. The highest CR rate was observed in untreated patients and in hypervascularized lesions; the rate of clinical sequels was low, clinical CR rates were high and there was no hematologic toxicity. This well-tolerated procedure provides good local disease control, but the high rate of deaths from extrahepatic progression suggests that systemic chemotherapy and long-step intraarterial perfusion be combined.
authors.affiliation: Servizio di Radiologia Diagnostica, Ospedale Bellaria-C.A. Pizzardi, Bologna.
authors.forename: R
authors.initials: R
authors.lastname: Roversi
authors.forename: G
authors.initials: G
authors.lastname: Cavallo
authors.forename: S
authors.initials: S
authors.lastname: Ricci
authors.forename: G
authors.initials: G
authors.lastname: Rossi
authors.forename: M
authors.initials: M
authors.lastname: Roversi
authors.forename: G
authors.initials: G
authors.lastname: Fiorentini
mesh_terms: D000328:Adult; D000368:Aged; D015687:Cell Hypoxia; D016461:Chemoembolization, Therapeutic; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000098:blood supply / Q000556:secondary* / Q000628:therapy*; D008297:Male; D008875:Middle Aged
vernacular_title: Perfusione antiblastica ipossica con blocco del flusso nella terapia delle metastasi epatiche: risultati preliminari.